Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deletion or Inhibition of NOD1 Favors Plaque Stability and Attenuates Atherothrombosis in Advanced Atherogenesis

  • González-Ramos, Silvia
  • Fernández-García, Victoria
  • Recalde, Miriam
  • Rodríguez-Sinovas, Cristina
  • Martínez-González, José
  • Andrés, Vicente
  • Martín-Sanz, Paloma
  • Boscá, Lisardo
© 2020 by the authors., Atherothrombosis, the main cause of acute coronary syndromes (ACS), is characterized by the rupture of the atherosclerotic plaque followed by the formation of thrombi. Fatal plaque rupture sites show large necrotic cores combined with high levels of inflammation and thin layers of collagen. Plaque necrosis due to the death of macrophages and smooth muscle cells (SMCs) remains critical in the process. To determine the contribution of the innate immunity receptor NOD1 to the stability of atherosclerotic plaque, Apoe−/− and Apoe−/− Nod1−/− atherosclerosis prone mice were placed on a high-fat diet for 16 weeks to assess post-mortem advanced atherosclerosis in the aortic sinus. The proliferation and apoptosis activity were analyzed, as well as the foam cell formation capacity in these lesions and in primary cultures of macrophages and vascular SMCs obtained from both groups of mice. Our results reinforce the preeminent role for NOD1 in human atherosclerosis. Advanced plaque analysis in the Apoe−/− atherosclerosis model suggests that NOD1 deficiency may decrease the risk of atherothrombosis by decreasing leukocyte infiltration and reducing macrophage apoptosis. Furthermore, Nod1−/− SMCs exhibit higher proliferation rates and decreased apoptotic activity, contributing to thicker fibrous caps with reduced content of pro-thrombotic collagen. These findings demonstrate a direct link between NOD1 and plaque vulnerability through effects on both macrophages and SMCs, suggesting promising insights for early detection of biomarkers for treating patients before ACS occurs., This work was supported by the Ministerio Economía, Industria y Competitividad/Agencia Estatal de Investigación (SAF2016-79490-R, RTI2018-094727-B-100, SAF2015-64767-R, SAF2016-75004-R, SAF2017-82436-R/RTC2017-6283-1, PID2019-108977RB-100), Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CB16/11/00405, CB16/11/00257, CB16/11/00222), Fundación Ramón Areces (CIUP18A3864), Consorcio de Investigación en Red de la Comunidad de Madrid, S2017/BMD-3686 and Fondo Europeo de Desarrollo Regional. The CNIC is supported by the Ministerio de Ciencia e Innovación, the Instituto de Salud Carlos III and the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant SEV-2015-0505)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Chronic treatment with acetaminophen protects against liver aging by targeting inflammation and oxidative stress

  • Brea, Rocío
  • Valdecantos, Pilar
  • Rada, Patricia
  • Alén, Rosa
  • García-Monzón, Carmelo
  • Boscá, Lisardo
  • Fuertes-Agudo, Marina
  • Casado, Marta
  • Martín-Sanz, Paloma
  • Valverde, Ángela M.
28 páginas, 7 figuras, 2 tablas, The liver exhibits a variety of functions that are well-preserved during aging. However, the cellular hallmarks of aging increase the risk of hepatic alterations and development of chronic liver diseases. Acetaminophen (APAP) is a first choice for relieving mild-to-moderate pain. Most of the knowledge about APAP-mediated hepatotoxicity arises from acute overdose studies due to massive oxidative stress and inflammation, but little is known about its effect in age-related liver inflammation after chronic exposure. Our results show that chronic treatment of wild-type mice on the B6D2JRcc/Hsd genetic background with APAP at an infratherapeutic dose reduces liver alterations during aging without affecting body weight. This intervention attenuates age-induced mild oxidative stress by increasing HO-1, MnSOD and NQO1 protein levels and reducing ERK1/2 and p38 MAPK phosphorylation. More importantly, APAP treatment counteracts the increase in Cd8+ and the reduction in Cd4+ T lymphocytes observed in the liver with age. This response was also found in peripheral blood mononuclear cells. In conclusion, chronic infratherapeutic APAP treatment protects mice from age-related liver alterations by attenuating oxidative stress and inflammation., SAF2016-75004-R, PID2019-108977RB-100 (AEI/FEDER, UE) to P. M-S. and M.C. and S2017/BMD-3686 (CM) to P. M-S, RTI2018-094052-B-100 (AEI/FEDER, UE), S2017/BMD-3684 (CM), Fundación Ramón Areces (Spain) and CIBERdem (ISCIII) to A.M.V., and PI17/00535 (ISCIII/FEDER, UE) to C. G-M., Peer reviewed